| dbo:abstract |
L'upadacitinib est une molécule inhibitrice sélectif de la janus kinase 1. (fr) ウパダシチニブ（Upadacitinib）は、メトトレキサート（活動性関節炎の治療に用いられる薬剤）の効果が不十分であったり、忍容性が得られなかったりした成人の中等度から重度の活動性関節リウマチの治療に用いられるヤヌスキナーゼ（JAK）阻害薬である。2019年に米国および欧州連合（EU）で医療用医薬品として承認されている。開発コードはABT-494である。製品名は「リンヴォック」(アッヴィ合同会社製造販売) 一般的な副作用としては、上気道感染症（感冒、副鼻腔感染症）、吐き気、咳、発熱などがある。 ウパダシチニブは、ヤヌスキナーゼと呼ばれる酵素の働きを阻害することで作用する。これらの酵素は、炎症を引き起こすプロセスの設定に関与しており、その作用を阻害する事で、関節の炎症を抑制する。 (ja) Upadacitinib, sold under the brand name Rinvoq, is a Janus kinase (JAK) inhibitor medication for the treatment of moderately to severely active rheumatoid arthritis and psoriatic arthritis in adults where methotrexate (a drug used to treat active arthritis) did not work well or could not be tolerated. It was approved for medical use in the United States and in the European Union in 2019, and was developed by the biotech company AbbVie. On January 14, 2022 Rinvoq received FDA approval for treating treatment refractory atopic dermatitis. Common side effects include upper respiratory tract infections (common cold, sinus infections), nausea, cough, and fever. Upadacitinib works by blocking the action of enzymes called Janus kinases. These enzymes are involved in setting up processes that lead to inflammation, and blocking their effect brings inflammation in the joints under control. (en) |
| dbo:alternativeName |
Rinvoq (en) |
| dbo:casNumber |
1310726-60-3 |
| dbo:chEMBL |
3622821 |
| dbo:class |
dbr:Janus_kinase_inhibitor |
| dbo:drugbank |
DB15091 |
| dbo:fdaUniiCode |
4RA0KN46E0 |
| dbo:kegg |
D10994 D11048 |
| dbo:medlinePlus |
a619051 |
| dbo:pubchem |
58557659 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Upadacitinib.svg?width=300 |
| dbo:wikiPageExternalLink |
https://druginfo.nlm.nih.gov/drugportal/name/upadacitinib |
| dbo:wikiPageID |
54089519 (xsd:integer) |
| dbo:wikiPageLength |
34798 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1123085865 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:American_College_of_Rheumatology dbr:Enzyme_inducer dbr:Monotherapy dbr:Blood_plasma dbr:Area_under_the_curve_(pharmacokinetics) dbr:Rheumatoid_arthritis dbr:Rifampicin dbr:Cytokine dbc:Organofluorides dbc:Pyrrolidines dbc:Trifluoromethyl_compounds dbc:Ureas dbr:Crohn's_disease dbr:Ruxolitinib dbr:Child–Pugh_score dbr:Nausea dbr:Oral_administration dbr:Psoriatic_arthritis dbr:Ciclosporin dbr:Clarithromycin dbr:Liver dbr:Lymphocytes dbr:Shingles dbr:Azathioprine dbr:Active_metabolite dbr:Cellulitis dbr:Tofacitinib dbr:Tuberculosis dbr:Tyrosine_kinases dbr:Janus_kinase_inhibitor dbr:Abatacept dbr:AbbVie dbr:Adalimumab dbr:Dupilumab dbr:Food_and_Drug_Administration dbr:Carboxylic_acid dbr:Disease-modifying_antirheumatic_drug dbr:Glucuronidation dbr:Glucuronide dbr:DAS28 dbr:Half-life dbr:Acyl dbr:Itraconazole dbr:Atopic_dermatitis dbc:AbbVie_brands dbc:Anti-inflammatory_agents dbc:Non-receptor_tyrosine_kinase_inhibitors dbr:Ketoconazole dbr:Bioaccumulation dbr:Immunomodulators dbr:C-reactive_protein dbr:CYP1A2 dbr:CYP2B6 dbr:CYP2C19 dbr:CYP2C9 dbr:CYP2D6 dbr:CYP3A dbr:CYP3A4 dbr:Placebo dbr:Pneumonia dbr:Immunosuppressant dbr:Methotrexate dbr:Midazolam dbr:Upper_respiratory_tract_infection dbr:Tyrosine_kinase_2 dbr:Oxidation dbr:Terminal_half-life dbr:First_pass_effect dbr:TNF_inhibitor dbr:Enzyme_substrate dbr:JAK-STAT_pathway dbr:JAK1 dbr:JAK2 dbr:JAK3 dbr:Janus_kinases dbr:Jakinib dbr:ACR20 dbr:Herpes dbr:Plasma_protein |
| dbp:atcPrefix |
L04 (en) |
| dbp:atcSuffix |
AA44 (en) |
| dbp:c |
17 (xsd:integer) |
| dbp:casNumber |
1310726 (xsd:integer) |
| dbp:chembl |
3622821 (xsd:integer) |
| dbp:chemspiderid |
44210449 (xsd:integer) |
| dbp:class |
dbr:Janus_kinase_inhibitor |
| dbp:dailymedid |
Upadacitinib (en) |
| dbp:drugbank |
DB15091 (en) |
| dbp:eliminationHalfLife |
-50400.0 |
| dbp:excretion |
Mainly unchanged in feces and urine (en) |
| dbp:f |
3 (xsd:integer) |
| dbp:h |
19 (xsd:integer) |
| dbp:iupacName |
-3 (xsd:integer) |
| dbp:iupharLigand |
9246 (xsd:integer) |
| dbp:kegg |
D10994 (en) D11048 (en) |
| dbp:legalAu |
S4 (en) |
| dbp:legalCa |
Rx-only (en) |
| dbp:legalEu |
Rx-only (en) |
| dbp:legalStatus |
Rx-only (en) |
| dbp:legalUk |
POM (en) |
| dbp:legalUs |
Rx-only (en) |
| dbp:licenceEu |
yes (en) |
| dbp:licenceUs |
Upadacitinib (en) |
| dbp:medlineplus |
a619051 (en) |
| dbp:metabolism |
Liver (en) |
| dbp:metabolites |
M4, an acyl glucuronide (en) |
| dbp:n |
6 (xsd:integer) |
| dbp:o |
1 (xsd:integer) |
| dbp:pregnancyAu |
D (en) |
| dbp:pregnancyCategory |
Not recommended (en) |
| dbp:proteinBound |
52.0 |
| dbp:pubchem |
58557659 (xsd:integer) |
| dbp:routesOfAdministration |
dbr:Oral_administration |
| dbp:smiles |
CC[C@@H]1CNC[C@@H]1c1cnc2cnc3[nH]ccc3n12 (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
WYQFJHHDOKWSHR-MNOVXSKESA-N (en) |
| dbp:synonyms |
ABT-494 (en) |
| dbp:tradename |
Rinvoq (en) |
| dbp:unii |
4 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Cite_web dbt:Clear dbt:IPAc-en dbt:Infobox_drug dbt:Portal_bar dbt:Refimprove_section dbt:Reflist dbt:Respell dbt:Short_description dbt:Unreferenced_section dbt:Update_after dbt:Use_American_English dbt:Use_dmy_dates dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Ebicite dbt:Fdacite dbt:Keggcite dbt:Stdinchicite dbt:Drugs.com dbt:Cytokine_receptor_modulators dbt:ClinicalTrialsGov dbt:Extracellular_chemotherapeutic_agents |
| dcterms:subject |
dbc:Organofluorides dbc:Pyrrolidines dbc:Trifluoromethyl_compounds dbc:Ureas dbc:AbbVie_brands dbc:Anti-inflammatory_agents dbc:Non-receptor_tyrosine_kinase_inhibitors |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment |
L'upadacitinib est une molécule inhibitrice sélectif de la janus kinase 1. (fr) ウパダシチニブ（Upadacitinib）は、メトトレキサート（活動性関節炎の治療に用いられる薬剤）の効果が不十分であったり、忍容性が得られなかったりした成人の中等度から重度の活動性関節リウマチの治療に用いられるヤヌスキナーゼ（JAK）阻害薬である。2019年に米国および欧州連合（EU）で医療用医薬品として承認されている。開発コードはABT-494である。製品名は「リンヴォック」(アッヴィ合同会社製造販売) 一般的な副作用としては、上気道感染症（感冒、副鼻腔感染症）、吐き気、咳、発熱などがある。 ウパダシチニブは、ヤヌスキナーゼと呼ばれる酵素の働きを阻害することで作用する。これらの酵素は、炎症を引き起こすプロセスの設定に関与しており、その作用を阻害する事で、関節の炎症を抑制する。 (ja) Upadacitinib, sold under the brand name Rinvoq, is a Janus kinase (JAK) inhibitor medication for the treatment of moderately to severely active rheumatoid arthritis and psoriatic arthritis in adults where methotrexate (a drug used to treat active arthritis) did not work well or could not be tolerated. It was approved for medical use in the United States and in the European Union in 2019, and was developed by the biotech company AbbVie. On January 14, 2022 Rinvoq received FDA approval for treating treatment refractory atopic dermatitis. (en) |
| rdfs:label |
Upadacitinib (fr) ウパダシチニブ (ja) Upadacitinib (en) |
| owl:sameAs |
wikidata:Upadacitinib dbpedia-fr:Upadacitinib dbpedia-ja:Upadacitinib https://global.dbpedia.org/id/2Y7pf |
| prov:wasDerivedFrom |
wikipedia-en:Upadacitinib?oldid=1123085865&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Upadacitinib.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Upadacitinib |
| is dbo:product of |
dbr:AbbVie |
| is dbo:wikiPageRedirects of |
dbr:Rinvoq dbr:Upadacitinib_hydrate dbr:Upadacitinib_hemihydrate dbr:ABT-494 dbr:ABT494 |
| is dbo:wikiPageWikiLink of |
dbr:List_of_drugs_granted_breakthrough_therapy_designation dbr:Janus_kinase dbr:Janus_kinase_inhibitor dbr:AbbVie dbr:Filgotinib dbr:Rinvoq dbr:Atopic_dermatitis dbr:ATC_code_L04 dbr:YWHAH dbr:Upadacitinib_hydrate dbr:Upadacitinib_hemihydrate dbr:ABT-494 dbr:ABT494 |
| is foaf:primaryTopic of |
wikipedia-en:Upadacitinib |
